arrow
B

Brigitte Michelsen

Diakonhjemmet Hospital
H指数:23
被引数:1,940

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis

定义巴思强直性脊柱炎疾病活动指数(BASDAI)截断值,以评估欧洲多国轴性脊柱关节炎患者队列中的疾病活动状态。

2025-12-020
OAAI
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

欧洲各国在组织治疗银屑病关节炎和轴向脊柱关节炎患者方面的国家医疗体系存在差异。

2025-06-010
OAAI
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
2025-05-011
OAAI
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
2025-02-280
OAAI
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic

类风湿关节炎或银屑病关节炎患者的间质性肺病起始生物制剂和对照: 来自5个北欧的数据

2024-09-011
OA
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
2024-08-190
OAAI
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
2024-07-011
OAAI
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
2024-04-151
OA
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
2024-02-253
OAAI
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naive Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

在常规护理中使用肿瘤坏死因子抑制剂治疗的12,262生物未接受过治疗的银屑病关节炎患者的患者报告结局 (PROs) 和缓解率

2024-01-150
OA
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
2023-10-016
OA
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

三分之一的欧洲中轴型脊柱关节炎患者通过常规护理肿瘤坏死因子抑制剂治疗达到疼痛缓解

2022-12-017
PRE
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
2022-04-2932
OAAI
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses

苏金单抗与肿瘤坏死因子抑制剂在脊柱关节炎中的一年治疗结果: 来自五个北欧生物注册的结果,包括超过10,000个疗程

2022-03-0821
PREAI
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial

英夫利昔单抗维持治疗期间治疗药物监测与标准治疗对免疫介导的炎性疾病患者疾病控制的影响随机临床试验

2021-12-21102
OA
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial
2021-05-04100
OA